"King of Cancer" liver cancer treatment has been a major breakthrough in the past ten years.

Liver cancer is a common digestive malignant tumor in the world, and china accounts for about half of all liver cancer patients in the world.
September 28th, Yu Jia, a member of the Chinese Academy of Sciences and president of Sun Yat-sen Hospital affiliated with Fudan University, released a clinical study that brings new ideas to the treatment of liver cancer, known as the "King of Cancer".
the clinical study, using the results of two national new drug creations, is the world's first phase III study to reach the end of the main study of PD-1 inhibitors for the first-line treatment of advanced liver cancer.
positive results mark a major breakthrough in liver cancer treatment in a decade of silence.
The study is a randomized, controlled, open multi-center Phase III clinical study using the innovative drug PD-1 inhibitor Dabershu® (Syndicate monoanti) developed by Cinda Bio, in a randomized, controlled, open multi-center phase III clinical study using the same ® (Bevaljuda monoantigen) for first-line treatment of advanced liver cancer.
clinical in-period analysis can reach the main research endpoint.
results show that compared with traditional standard targeted drug therapy, the treatment program significantly prolongs the patient's progress-free survival and total survival.
results will be presented at the upcoming International Medical Conference.
It is known that this is the world's first PD-1 monoclonal antibody and anti-VEGF monoclonal antibody combined for advanced liver cancer treatment Phase III clinical research, this positive result marks the "silent" decade of liver cancer treatment ushered in a major new breakthrough, is Another example of China's pharmaceutical innovation to the world.
, there are about 841,000 new liver cancer patients and 782,000 liver cancer deaths worldwide each year.
china is a big country with liver cancer, with a incidence rate of 26.92 per 100,000 and a mortality rate of 23.72 per 100,000.
morbidity and mortality of liver cancer ranked 4th and 2nd respectively in china's malignant tumors.
Liver cancer has the characteristics of early diagnosis, rapid progress and poor prognosis, the overall five-year survival rate of liver cancer in China is only 12.1%, which seriously threatens the life and health of our people and causes serious disease burden to society and family.
Many patients with liver cancer are in their late stages and have lost surgery, " said Yu Jia, a member of the Chinese Academy of Sciences and president of Sun Yat-sen Hospital affiliated with Fudan University.
The first-line treatment of advanced liver cancer approved in China is mainly targeted treatment and systematic chemotherapy, but the role of these therapies is limited, it is usually difficult to control the disease after treatment, or temporarily controlled but quickly relapsed, progress and drug resistance problems.
from other global clinical studies, our study included nearly 600 patients, all of whom were liver cancer patients in China.
compared with liver cancer patients worldwide, more than 85% of liver cancer patients in China are caused by hepatitis B infection, which makes the prognosis of Chinese patients and the efficacy of traditional treatment significantly worse than that of patients worldwide.
In this study, the combined treatment of Dabshu ® and Dayo ® provides the world's largest, hepatitis B-related liver cancer patients to receive immune co-treatment and traditional targeted treatment of comparative data, for improving the efficacy and prognosis of liver cancer patients in China is of great significance, but also to the treatment of hepatitis B-related liver cancer patients around the world to bring new hope. During the
study, many patients were unable to return to the hospital in time for treatment and examination, and all the researchers and Thyda Bio's clinical research team overcame the difficulties and stood with the patients, doing their best to help them in the first place.
, despite being affected by all aspects of the outbreak, finally completed the landmark study in time.
(Syndicate® is a PD-1 inhibitor that is of great concern in the field of tumor immunotherapy.
from the therapeutic mechanism, the surface of cancer cells produces a special protein PD-L1, which, when combined with PD-1 on the surface of immune cells, can give immune cells an "illusion" and lose the ability to kill cancer cells.
role of PD-1 inhibitors is to "put a knife" between the two, so that PD-1 and PD-L1 can not be combined, so that immune cells re-infested to identify and kill the role of cancer cells.
Daju and ® (Beval pearl monoantitor) belong to angiogenesic inhibitors, the principle mechanism of anti-tumor is by blocking the endothor endotrophic growth factor VEGF, inhibiting angiogenesia of the tumor, cutting off the blood supply in the tumor area, inhibiting the growth and metastasis of the tumor, inducing tumor apoptosis, so as to achieve therapeutic purposes through the mechanism of "starving" the tumor.
in addition to its established anti-angiogenespheric effects, dabshu®® can be further enhanced by inhibiting VEGF-related immunosuppression and promoting the response of immune cells to tumor antigens.
industry insiders said that Daboshu ® and Da yutong® are the country's major new drug creation special results, developed by Xinda Biopharmaceuticals.
the use of these two drug combination therapies means that China's innovative biopharmaceutical companies have reached a high level of research and development.
is a typical case of China's scientific and technological innovation in the field of people's livelihood.
new therapy pioneered by Xinda Bio has effectively promoted the industrialization of scientific and technological achievements, and through medical innovation, more Chinese patients can enjoy the health benefits of scientific and technological progress.
both drugs are currently included in the National Health Insurance List, and Dabershu's Medicare adaptation is the treatment of at least a recurrence of second-line system chemotherapy or recurring classic Hodgkin's lymphoma.
the same health-care adaptation is metastatic rectal cancer and advanced, metastatic or relapsed non-small cell lung cancer.
chinese innovative drugs with international quality benefit patients with high quality and low price, and effectively improve the survival of patients while reducing the burden on patients' families.
it is understood that Cynda Bio has also jointly established the China Cancer Foundation health public welfare poverty alleviation project, poor patients can use Daboshu free of charge for treatment, to achieve accurate poverty alleviation, so that poor patients can also enjoy advanced treatment methods.
This year is the year of the national medium- and long-term science and technology development planning outline, as one of the 16 major scientific and technological projects of the new drug creation science and technology major special progress, new drug creation projects Daboshu and The same results, reflecting China's drug research and development innovation capacity, has made great progress.
outline of the "Healthy China 2030" plan, the overall cancer survival rate should be increased by 15% by 2030.
opinion on the implementation of healthy China action issued by the State Council, it is also proposed that the overall five-year survival rate of cancer by 2022 and 2030 should not be less than 43.3% and 46.6%, respectively.
as a research and development-driven pharmaceutical company, Xinda Bio actively responds to the implementation of the "Healthy China 2030" strategy through innovative practices in the pharmaceutical field, and fulfills corporate social responsibility, providing a solid impetus for the sustainable development of the health cause.
References: 1. Tang Wei. On the Road to The Prevention and Control of Liver Cancer in China. Chinese Journal of Oncology, 2015 (37): 643.2. Jin Hua, Huang Vocational Sister, Zhang Tianqi, etc.. Progress in comprehensive treatment of advanced and middle-stage liver cancer based on interventional therapy. Electronic Journal of Liver Cancer, 2019 (4): 27-31.3. A preliminary study of the role and mechanism of DSG2 in hepatocellular carcinoma. 2019.4. Feng Guoying, Shi Zhengrong. The predicted value and controversy of the prognosis of hepatocellular carcinoma by the programmed cell death complex 1 licquer and the soluble procedural cell death lid. Journal of Clinical Hepatopathy, 2020 (8). Network Source: Web Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.